How many rheumatologists are managing psoriasis themselves? Or dermatologists managing arthritis themselves? Survey shows <50% rheum collaborate with derm Need updated EMRs and additional education Abs#1502 @RheumNow #ACR22 https://t.co/1okhxFAbUS

⚡️PRESTO⚡️ 📈PsA prediction tool in psoriasis Risk of PsA at 1yr ⬆️: 👉younger 👉male 👉FHx Psoriasis 👉back stiffness 👉stiffness level 👉nail pitting 👉biologic use 👉⬆️ pain and global health (AUC 72.3,95%CI 65.5,79.1) #ACR22 @RheumNow Abst#1612

Prevalence of uveitis in patients with PsA was about 5%. Uveitis rate decreased w/ anti-TNFα monoclonal antibodies and increased w/ ETN and SECU. Abs 1159 #ACR22 @RheumNow https://t.co/BtHMQ6apNI https://t.co/uZEYVQdiOU

• Uveitis in Psoriatic Arthritis: Study of 406 Patients in a Single University Ce…

Ab1486 #ACR22 @Keith_Colaco: Disease-specific CV Risk Prediction Model for PsO, PsA Prediction base model w only traditional CV risks excellent (AUC 85.5) Expanded model w damaged jts did not improve risk discrimination @Rheumnow https://t.co/DMlOreW9zK

Ab1508 #ACR22 Enthesitis on PET/CT 20 untreated PsA pts w/ total body PET/CT All 20 (100%) pts had entheseal inflammation 127/543 (~1/4) entheses showed inflammation @RheumNow https://t.co/OQCBWW70bt

Does Bimekizumab, anti-IL17F, work in PsA? #ACR22 @RheumNow Abstract #L02 💊Phase 3, randomized, placebo-controlled study 💉Biologic naive patients ✋ Week 52: 53-54% BKZ groups achieved ACR502 (v. 50% in TNFi) 📍benefits sustained to week 52 🛑No new safety signals

FOREMOST results: Early oligoarticular PsA pts experienced high disease burden/decreased QoL. Small joint involvement, although less commonly seen in oligoarticular PsA, was the most frequently observed pattern. Abs 1018 #ACR22 @RheumNow https://t.co/wBldKM9MTq https://t.co/qOVZd8aTyR

• Characterization of Joint Distribution and Disease Burden in Patients with Earl…

Post hoc analysis of 3 PsA/SPA trials: no effect of tobacco 🚬 on TOFA efficacy But numerically higher TEAEs Contrasting w/ data from real world TNF Interesting data but small sample size & events N https://t.co/gv8uvcThMD Abs#1036 #ACR22 @Rheumnow https://t.co/HCJT0XF1tg

• Efficacy and Safety of Tofacitinib in Patients with Psoriatic Arthritis or Anky…

DANBIO registry: 1600+ pts RA, AxSpA, PsA Infiximab biosimilar to biosimilar switch (CT-P13 -> GP1111) Maintenance at 1yr: >80% > withdrawal in original IFX naive, but higher BL DA Do second time switchers do better because of past switch experience? Abs#1112 #ACR22 @RheumNow https://t.co/IgjhGLVESz

@AlexisOgdie et al: PsA pts who were MDA, DAPSA LDA, or ACR50 responders vs non-responders reported clinically meaningful improvements across PROs including pain, physical function, fatigue, and work productivity. Abs 1019 #ACR22 @RheumNow https://t.co/MK13sXS3Or https://t.co/TfCrQMV2JX

• Association Between Stringent Clinical Measures of Disease Activity and Clinica…

Biosimilar to biosimilar effective in treatment of RA/PsA/AxSpA. Large study looking at infliximab biosimilar switching - resulted in high retention rates and virtually no change in disease activity. @RheumNow #ACR22 Abs#1112 https://t.co/uNRXLewo4M

The greater the PsAID score, the more likely escalation in PsA treatment. Noted significant correlation between PsAID and physician global scores. Do you use PsAID in your clinic? Abs 1028 #ACR22 @RheumNow https://t.co/gcjm2XgPE3 https://t.co/bKPtXz5Nw8

• How Does PsAID Implementation Affect Treatment Intensification and Patient Sati…

Do patients with PsA like online wellness programs? #ACR22 @RheumNow 🌈 186 patients, 86% women, 90% White 🌈sleep and nutrition were highly rated for wellness 🌈cost and fatigue barriers to adopting wellness behaviors 🌈 27% were open to an online wellness program

BASDAI and ASDAS performed similarly in axPsA pts, both demonstrating weak correlations w/ peripheral arthritis and moderate/strong correlations w/ pt fatigue and pain. Abs 1037 #ACR22 @RheumNow https://t.co/WRQx1hkIll https://t.co/kJVIWyVv2w

• Performance of BASDAI vs. ASDAS in Evaluating Axial Involvement in Patients wit…